On May 2, 2024, Sanofi submitted a 6-K filing reporting on several significant events from April, including promising Phase 2 data for frexalimab in multiple sclerosis and a successful primary endpoint in the LUNA 3 study for rilzabrutinib, along with a publication showing an 82% reduction in RSV hospitalizations in infants.